<DOC>
	<DOCNO>NCT01282879</DOCNO>
	<brief_summary>Antifungal prophylaxis use patient treated glucocorticoid graft-versus-host disease ( GVHD ) follow allogeneic hematopoietic stem-cell transplantation ( HSCT ) . Although fluconazole widely use antifungal prophylactic agent allogeneic HSCT , fluconazole prophlaxis show limit protective role IFIs , effective invasive aspergillosis . In addition , NCCN guideline prevention treatment cancer-related infection recommend antifungal prophylaxis patient significant GVHD resolution GVHD use Posaconazole , Voriconazole , Echinocandin , Amphotericin B . However , National Health Insurance System , none drug give prophylactically except itraconazole oral solution IFIs . Itraconazole oral solution show excellent bioavailability good efficacy aspergillus fluconazole resistant candida infection.Based finding , perform prospective multicenter study evaluate efficacy , safety long-term outcome itraconazole oral solution prophylaxis IFIs patient treat systemic corticosteroid GVHD allogeneic HSCT .</brief_summary>
	<brief_title>Evaluation Antifungal Prophylaxis Graft-versus-host Disease ( GVHD ) Patients</brief_title>
	<detailed_description>Eligible patient provide informed consent form administer itraconazole oral solution ( 200mg bid initially , swash swallow ) either patient outpatient set . Treatment initiated time within 10 day start systemic immunosuppressive therapy . Itraconazole oral solution dose adjust accord liver function test : 1 ) case - AST/ALT level 5-10 time UNL bilirubin/ALP level 2-5 time UNL , itraconazole dose reduce half ( i.e . itraconazole 200mg po daily 100mg bid ) ; 2 ) case - AST/ALT level &gt; 10 time UNL bilirubin/ALP level &gt; 5 time UNL , itraconazole stop . GVHD treatment give per center 's policy : With respect acute GVHD , prednisone ( 1-2mg/Kg/day ) oral iv give top calcineurin inhibitor ( CNI ) GVHD prophylaxis . For chronic GVHD , various type frontline regimen permit include CNI+prednisone ( PD ) , PD alone , CNI+PD+mycophenolate mofetil ( MMF ) , MMF+PD . Various dose PD accept least 0.5mg/Kg/day . For example , SMC , case mild grade cGVHD high risk feature , moderate grade cGVHD , CNI plus PD , 0.5mg/kg/day give initially . In case severe grade cGVHD , CNI plus PD , 1.0mg/Kg/day give . Itraconazole maintain PD taper 10mg/day case PD alone therapy group , PD stop case CNI+PD CNI+PD+MMF MMF+PD group , etc . In addition , patient receive itraconazole oral suspension : 1 ) Development proven probable IFIs , 2 ) Severe toxicity ( liver function abnormality - AST/ALT level &gt; 10 time UNL bilirubin/ALP level &gt; 5 time UNL , 3 ) Worsening GVHD require second line therapy steroid refractory GVHD ( situation , investigator could stop itraconazole oral solution potential drug interaction itraconazole oral solution 2nd line GVHD drug prolong use itraconazole oral solution could hazardous patient ) , 4 ) Need switch antifungal agent treatment prolong febrile episode relate systemic infection , thus require systemic antifungal treatment , 6 ) Withdrawal study participation ( patient 's decision ) , 7 ) Death .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<criteria>Patients develop developed acute chronic GVHD within last 10 day require systemic immunosuppressive therapy corticosteroid orwithout immunosuppressive agent include calcineurin inhibitor . 1. acute GVHD , grade 24 2. chronic GVHD , mild grade high risk moderate severe grade Written inform consent form Aspartate transaminase alanine transaminase level &gt; 10 time UNL Bilirubin alkaline phosphatase level &gt; 5 time UNL Active chronic hepatitis virus B C infection require antiviral therapy Estimated life expectancy &lt; 30 day History allergy , sensitivity , serious reaction itraconazole oral solution Previous history Zygomycosis Evidence active fungal disease include high galactomannan titer 0.5 , within 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Itraconazole oral solution</keyword>
	<keyword>invasive fungal infection</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>Graft v Host Disease</keyword>
	<keyword>transplantation</keyword>
</DOC>